News

Proposed Medicaid changes could lead to 1,500 excess deaths and $135 billion in economic losses annually, impacting health care and rural communities.

The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

In this interview, Sarah Morris, chief product officer of Audere, explains why they chose to focus on women and young girls and how they have tailored their program to reach them.

Employers increasingly shift health benefit costs to workers in 2026, while prioritizing mental health and innovative affordability strategies.

A scleroderma patient in a Sylvester Comprehensive Cancer Center trial was recently successfully treated with CAR T-cell lymphoma therapy, in what researchers are calling an “immunological reset.”

Audere is closing gaps in HIV care and education with the help of Aimee, their artificial intelligence companion designed to reach women and young girls in South Africa, according to Sarah Morris, CPO of Audere.

Humana has released details about additional, upcoming organizational improvements to encourage a faster prior authorization process, lessen system waste and increase transparency.

This biosimilars market report focuses on rising market complexity and recent activity, including two new approvals and four launches in Q2.

A national preexposure prophylaxis (PrEP) program would streamline access and improve HIV outcomes but unfortunately never came to pass because of a lack of funding, according to Jeremiah Johnson, executive director, PrEP4All.

Here’s what you missed this week on Managed Healthcare Executive.

Driven by expensive drugs, hospital stays and growing behavioral health needs, healthcare spending is expected to keep rising—encouraging insurers to tighten oversight and explore new ways to control costs.

Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of PrEP4All.

The high cost of pharmaceutical products coupled with a lack of federally funded HIV programs create barriers for preexposure prophylaxis (PrEP) access according to Jeremiah Johnson, executive director, PrEP4All.

Autoimmune diseases, such as vitiligo, celiac disease and rheumatoid arthritis, are not tied to aluminum exposure from vaccines, according to a nationwide cohort study of approximately 1.2 million children done in Denmark.

A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said there were more risks than benefits for menopausal women taking hormone therapy.

Long-acting injectable PrEP may improve access, protection and adherence, especially for young people and pregnant women, according to Hasina Subedar, a senior technical advisor at South Africa’s National Department of Health, who spoke with editors at IAS 2025 in Kigali, Rwanda.

This new Shingrix vaccine presentation eliminates the need for reconstitution, simplifying the administration process for healthcare professionals.

Mulugeta Gebregziabher, Ph.D., spoke with Managed Healthcare Executive ahead of his presentation at IAS 2025 in Kigali, Rwanda, about the risks posed by U.S. cuts to global HIV prevention funding.

Integrating people-centered HIV care with primary health care is essential to improving access, equity and health outcomes, but doing so successfully requires coordinated policies, digital transformation, community engagement, and sustained funding, according to experts at IAS 2025.

At the IAS 2025 conference in Kigali, Rwanda, Banky Olatosi, M.P.H., M.S., Ph.D., of the University of South Carolina, shed light on how systemic racism and social determinants of health influence HIV diagnoses and care across U.S. regions.

While successes have been seen because of HIV self-testing, funding cuts to USAID and PEPFAR will make continued research difficult, according to Anna Bershteyn, Ph.D., associate professor in the Department of Population Health, NYU Grossman School of Medicine.

In this interview, Matthew Yarnell, president of SEIU Healthcare, Pennsylvania, a healthcare union, condemns Trump’s $1 trillion Medicaid cut, saying that more than a quarter of a million Pennsylvanians will lose their healthcare coverage as a result.

According to experts at the IAS 2025 meeting in Kigali, Rwanda, AI revolutionizes HIV vaccine development by enhancing design, data analysis and clinical trials, especially in low-income regions, creating a faster progress.

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its impact depends on access, patient-centered care and affordability.

Experts, such as Lloyd Mulenga, M.Sc., M.B., Ch.B., Ph.D., discuss long-acting injectable HIV PrEP's potential in Zambia, emphasizing community involvement and sustainable rollout amid funding challenges.

Investigational interstitial lung disease (ILD) drug, efzofitimod, shows early signs of efficacy in patients with pulmonary sarcoidosis and SSc-ILD (scleroderma-related ILD), according to new trial data.

Leqselvi (deuruxolitinib) 8 mg tablets are approved for adults with severe alopecia areata, a disease that causes the immune system to attack hair follicles, leading to partial or complete hair loss on the scalp and body.

Integrating HIV and sexual health care is essential for improving outcomes, but global stigma, funding cuts—especially the defunding of USAID—and structural barriers like limited access and political resistance continue to hinder progress, experts emphasized at IAS 2025.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic kidney disease (CKD) associated with type 2 diabetes. This new approval extends its use to a broader patient population.

There is currently a movement to “de-medicalize" PrEP by pushing for more availability at more casual settings than government clinics, according to Anna Bershteyn, Ph.D., associate professor in the Department of Population Health, NYU Grossman School of Medicine.